MGI news

The Minneapolis company said Saligen sales for the third quarter ending Sept. 30 will be lower than analyst projections as a result of its tablet sampling marketing program. MOGN now expects third quarter product sales of $300,000 to $400,000. The company previously forecast third-quarter sales to be substantially lower than the $3.3 million reported in the second quarter.

To build initial awareness of drug, which treats dry mouth related to head and neck cancer therapy, MOGN had been providing samples of 100-tablet bottles to targeted physician groups. MOGN said it will continue the sampling program into October, at which time it will scale back the sample to 21-tablet bottles. ...